ARK Invest's position in ADPT, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 1,961,671 | $57.8M | 2.93% | #13 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | ARKG | Sell | Trimmed | 108,120 | $2.4M |
| 2026-07-08 | ARKG | Sell | Trimmed | 32,775 | $661K |
| 2026-07-07 | ARKG | Sell | Trimmed | 72,323 | $1.5M |
| 2026-05-14 | ARKG | Sell | Trimmed | 35,073 | $462K |
| 2026-05-13 | ARKG | Sell | Trimmed | 12,372 | $162K |
| 2026-05-07 | ARKG | Sell | Trimmed | 33,134 | $487K |
| 2025-12-22 | ARKG | Sell | Trimmed | 35,555 | $619K |
| 2025-12-18 | ARKG | Sell | Trimmed | 35,311 | $583K |
| 2025-12-10 | ARKG | Sell | Trimmed | 35,379 | $557K |
| 2025-12-09 | ARKG | Sell | Trimmed | 90,807 | $1.3M |
| 2025-12-08 | ARKG | Sell | Trimmed | 108,578 | $1.6M |
| 2025-12-05 | ARKG | Sell | Trimmed | 195,141 | $2.9M |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects…
See ADPT's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open ADPT on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.